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Caspase-mediated cleavage of raptor participates in the
inactivation of mTORC1 during cell death
R Martin1, C Desponds1, RO Eren1, M Quadroni1,2, M Thome1 and N Fasel1
The mammalian target of rapamycin complex 1 (mTORC1) is a highly conserved protein complex regulating key pathways in cell
growth. Hyperactivation of mTORC1 is implicated in numerous cancers, thus making it a potential broad-spectrum
chemotherapeutic target. Here, we characterized how mTORC1 responds to cell death induced by various anticancer drugs such
rapamycin, etoposide, cisplatin, curcumin, staurosporine and Fas ligand. All treatments induced cleavage in the mTORC1
component, raptor, resulting in decreased raptor–mTOR interaction and subsequent inhibition of the mTORC1-mediated
phosphorylation of downstream substrates (S6K and 4E-BP1). The cleavage was primarily mediated by caspase-6 and occurred at
two sites. Mutagenesis at one of these sites, conferred resistance to cell death, indicating that raptor cleavage is important in
chemotherapeutic apoptosis.
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INTRODUCTION
The mammalian target of rapamycin (mTOR) is an evolutionary
conserved protein complex positively regulating anabolic path-
ways (protein synthesis, energy metabolism, cell survival and
cytoskeletal organization) but also repressing catabolic pathways
(autophagy and apoptosis). Two different mTOR complexes
exist:1,2 mTOR complex 1 (mTORC1) and mTOR complex 2
(mTORC2). These two complexes are both composed of the
mTOR serine/threonine protein kinase, deptor,3 mLST84 and tti1/
tel2.5 In addition, mTORC1 is composed of speciﬁc proteins: the
regulatory-associated protein of mTOR (raptor)6 and pras40,7
whereas mTORC2-speciﬁc proteins are the rapamycin-insensitive
companion of mTOR (rictor),8,9 mSin110 and protor 1 and 2.11
Raptor acts as a scaffold protein inside mTORC1, maintaining
the dimerization state of the complex12–14 and recruiting
substrates to the kinase domain of mTOR.15 In this context, the
initiation of the protein translation machinery is controlled at two
different levels by raptor and mTOR. On one hand, raptor binds
and recruits the eukaryotic translation initiation factor 4E-binding
protein 1 (4E-BP1) to mTORC1, allowing its phosphorylation by
mTOR at Thr37/46, which induces the release of 4E-BP1 from the
eukaryotic translation initiation factor 4E (elF4E) and gives rise to
the activation of cap-dependent mRNA translation.16,17 On the
other hand, raptor binds to the p70 S6 kinase 1 (p70 S6K1)
enabling its phosphorylation by mTOR at Thr389, which induces
p70 S6K1 to phosphorylate the S6 ribosomal protein and activate
protein synthesis.18,19
As a central regulator of cell growth, mTORC1 is frequently
hyperactivated in a large proportion of human cancers,20 leading
to tumorigenesis. This is mainly due to mutations occurring in
upstream regulators of mTORC1 (such as RTK, PI-3K, Akt, Erk, PTEN
and p53),1 giving rise to hyperactive mTORC1, increase in
phosphorylation of its downstream targets and thus, enabling
abnormal proliferation. In addition, activating mutations have
been identiﬁed in the MTOR gene, leading to hyperactivation of
the mTOR pathway.21
In this context, the mammalian target of rapamycin has been
largely studied as a target for cancer treatments. Inhibitors of
mTOR like rapamycin (an allosteric inhibitor) and its analogs
(rapalogs) were developed to target this complex. However, the
presence of negative feedback loops in the mTOR pathway may
have a role in the limitation of treatment efﬁcacy of rapalogs.22–27
To counteract this effect, inhibitors of the mTOR kinase activity
were developed and unlike rapamycin, a more robust repression
of 4E-BP1 phosphorylation was reached with the use of these
inhibitors.24,26 Recently, new strategies have been developed to
target mTORC1 and its upstream regulators at the same time in
order to block the oncogenic cascade. Promising results were
obtained using dual PI-3K/mTOR inhibitors.23
Common chemotherapies against various types of cancer are
using etoposide and cisplatin to induce cancer cell apoptosis.28,29
Cisplatin is a platinium-based drug creating DNA crosslinking and
triggering apoptosis, whereas etoposide is a topoisomerase
inhibitor causing DNA strand breaks and promoting apoptosis.
These two drugs are also known to affect the mTOR pathway by
reducing phosphorylations of 4E-BP1 and S6K.30–32
Natural compounds are now emerging as alternative therapies
for cancer treatments such as curcumin, the polyphenol com-
pound extracted from rhizome of the plant Curcuma longa. This
compound has been shown to alter proliferation of cancer cells
and also to disrupt the mTORC1 by weakening mTOR–raptor
interaction.33–35
In an attempt to understand more deeply the molecular
mechanisms of anticancer drugs targeting mTORC1, we studied
the cell death cascade induced by different drugs on lymphoma
cell lines. We report here that rapamycin, cisplatin, etoposide,
curcumin, staurosporine (STS) and Fas ligand (FasL) induced
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caspase-mediated cleavage of raptor and inactivation of the
mTORC1, a critical step for apoptosis induction.
RESULTS
Raptor is cleaved in various drug-treated lymphoma cell lines
To investigate the effect of anticancer drugs on mTORC1, we
incubated lymphoma cell lines with cisplatin or etoposide. As
shown in Figure 1a, treatment of B lymphoma cell lines (BJAB and
SUDHL4) for 15 h with cisplatin induced a cleavage of the full-
length raptor protein of 150 kDa into a smaller fragment of
approximately 100 kDa. Similar observations were made after 15 h
of etoposide treatment in T (Hut78) and B (BJAB) cell lymphomas
(Figure 1b).
The regulatory-associated protein of mTOR (raptor) is composed
of three evolutionarily conserved domains: a raptor N-terminal
(N-term) conserved domain (also called RNC), three HEAT repeats
and seven WD repeats, which are protein interaction domains
mediating the raptor–mTOR interaction.14 This interaction has
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Figure 1. Raptor cleavage upon drug treatment in various T lymphoma and B-cell lines. Lymphoma T (Jurkat, Hut78) or B-cell lines (HBL-1,
BJAB, SUDHL4) were incubated with 50 μM of cisplatin for 15 h (a), 50 μM of etoposide for 15 h (b), 25 μM of curcumin for 15 h (c), 1 μM of
rapamycin for 16 or 48 h (d), 50ng/ml of FasL for 4 or 8 h (e and f) and with 2 μM of STS for 2, 4, 6, 8 or 24 h (g and h). Cell lysates were then
analyzed on 8% SDS-PAGE. (i) Scheme of raptor protein highlighted with the region recognized by the raptor mAb and with the putative
cleavage site. RNC, raptor N-term conserved domain; HEAT, Huntingtin, elongation factor 3 (EF3), protein phosphatase 2A (PP2A), and the
yeast kinase TOR1; WD, tryptophan-aspartic acid (WD) dipeptide.
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been previously shown to be weakened after curcumin or high-
dose rapamycin treatments.34,36 For this reason, we next
investigated the effect of curcumin or rapamycin on lymphoma
cell lines. After treatment with curcumin or rapamycin, raptor was
also cleaved into a 100 kDa fragment in B lymphoma cell lines
(Figures 1c and d), supporting the previously reported destabiliz-
ing effect of curcumin and rapamycin on mTORC1. As cisplatin,
etoposide, curcumin and rapamycin were reported as apoptosis
inducers,33,37–39 we decided to use two other well-described cell
death inducers, STS and FasL, to assess the correlation between
cell death and raptor processing.38,40 Treatment of T and B
lymphoma cell lines with FasL (Figures 1e and f) or STS (Figures 1g
and h) both induced a clear processing of raptor into a 100 kDa
fragment. Interestingly, we used a rabbit monoclonal antibody
(mAb) recognizing the N-term part of raptor, which suggested
that, based on the size of cleaved fragment, the observed
cleavage occurred within the C-terminal (C-term) part of raptor,
probably between the HEAT repeats and the WD repeats
(Figure 1i).
Taken together, these data showed that anticancer drug
treatments as well as apoptosis inducers gave rise to a cleavage
of raptor, an essential scaffold protein of the mTORC1.
Raptor cleavage is mediated by caspases
Different proteases activated during cell death can be responsible
for the observed cleavage of raptor. For this reason, we decided to
test the following cell permeable protease inhibitors and verify
whether they affected raptor cleavage: a general caspase inhibitor
(z-VAD-fmk), a cathepsin inhibitor (E64D) and a furin inhibitor
(Dec-RVKR-cmk). Jurkat T cells were used as the processing of
raptor was easily induced in this cell line. Treatment of Jurkat
T cells for 4 h with FasL induced a clear cleavage of raptor into the
above-described 100 kDa fragment, and with lower efﬁciency, into
an additional, smaller fragment of 70-80 kDa (Figure 2a). The
addition of the caspase inhibitor (z-VAD-fmk) completely abol-
ished the cleavage of raptor and well-known apoptotic events,
whereas the cathepsin and furin inhibitors had no effect on the
processing. In addition, z-VAD-fmk efﬁciently inhibited raptor
cleavage induced by intrinsic apoptosis inducers: STS or cisplatin
(Figures 2b and c).
These results indicated that activation of caspases, by extrinsic
or intrinsic apoptosis inducers, mediated raptor processing into
molecular species of 100 kDa and 70–80 kDa.
Active recombinant caspase-1 and caspase-6 can cleave raptor
in vitro
To determine more precisely which caspase(s) could be implicated
in raptor cleavage, recombinant caspase(s)-1, -2, -3, -6, -7, -8 and -9
were incubated with Jurkat T-cell lysates (Figure 3a). In
comparison with cells treated with STS, used a positive control,
caspase-6 was the only caspase that induced processing of raptor
into the expected 100 kDa band, whereas caspase-1 was able to
cleave raptor into two smaller fragments of roughly 70 and
80 kDa. Although recombinant caspase-1 and -6 induced an
in vitro time-dependant cleavage of raptor in Jurkat T-cell lysates
(Figure 3b), activation of the inﬂammatory caspase-1 in bone
marrow-derived macrophages (BMDMø) did not highlighted
processing of raptor, suggesting that caspase-1 most likely did
not account for physiological raptor cleavage (Supplementary
Figure S1).41
As recombinant caspase-6 generated similar processing of
raptor than treatment with pro-apoptotic drugs, we decided to
investigate this processing in more detail. In Figure 4a, the
cleavage of the poly (ADP-ribose) polymerase (PARP) by caspase-3
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Figure 2. Inhibition of raptor processing by z-VAD-fmk. Jurkat T cells were pre-incubated for 30 min with different inhibitors (z-VAD-fmk, E64D
or Dec-RVKR-cmk) and then treated with FasL for 4 h (a), STS for 4 h (b) or with cisplatin for 16 h (c). Cell lysates were then analyzed on 8% or
12% SDS-PAGE.
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and -7,42 and the cleavage of lamin A/C by caspase-643,44 revealed
the speciﬁcity of these active recombinant caspases in Jurkat T-cell
lysate. As shown before, caspase-6 was the only executioner
caspase able to cleave raptor in cell lysates and addition of z-VAD-
fmk abolished processing of raptor, conﬁrming that the cleavage
was depending on the catalytic activity of recombinant caspase-6
(Figures 4a and b).
To clarify whether the processing of raptor obtained with
recombinant caspases occurred directly or in two steps, as a
consequence of activation of another protease in the lysates by
these recombinant caspases, we used a recombinant mTORC1
composed of essential proteins required for mTOR activity
(Figure 4c). The cleavage of raptor was observed in the presence
of caspase-6 and also with caspase-3, yielding a fragment with the
same molecular mass (100 kDa) than observed after apoptosis
induction. This processing was completely abolished after addition
of z-VAD-fmk. Cleavage of full-length raptor (150 kDa) was less
strong with caspase-3 when compared with caspase-6, and
caspase-7 was not able to cleave recombinant raptor inside the
mTORC1 (Figure 4d).
Taken together, these results showed that recombinant
caspase-6 efﬁciently cleaved raptor in Jurkat T-cell lysates as well
as recombinant raptor inside mTORC1. Whereas raptor could not
be cleaved in cell lysates by other recombinant caspases such as
caspase-3 and -7, recombinant caspase-3 was able to cleave
recombinant raptor inside mTORC1, suggesting that different
caspases could be implicated in raptor processing.
Caspase-6 has a role in raptor processing in vivo under apoptotic
conditions
To conﬁrm in vivo caspase-6-mediated processing of raptor,
we used a caspase-6 knockout (KO) chronic myelogenous
leukemia cell line (KBM-7) generated by gene trapping
(Figure 4e). As expected, the cleavage of caspase-6 and lamin
A/C were only observed in WT cells after STS or FasL treatments
and not in caspase-6 KO cells. Raptor processing was clearly
reduced (but not completely abolished) in caspase-6 KO
compared with WT KBM-7 cells. This suggests that caspase-6 has
a major role in raptor processing in vivo, but other caspases most
likely contribute to this process.
Raptor is cleaved at the C-terminus part after DDADD residues
It is known that caspases are exclusively recognizing the
negatively charged aspartic acid (or aspartate (Asp, D)) residues
in the P1 position of the cleavage site. Two potential cleavage
sites, corresponding to the size of the cleaved fragment, were
found within the C-term part between the HEAT repeats and the
WD repeats: DDADD (UniProtKB: Q8N122, amino acids 939–943)
and AVADKD (amino acids 1039–1044) (Figure 5a). To understand
if these residues were involved in the caspase-mediated cleavage
of raptor, Jurkat T cells were transiently transfected by electro-
poration with raptor WT or mutated constructs (DDAAA or
AVAAKA) (Figures 5b and c). Similar expression levels were
achieved for the WT, DDAAA and AVAAKA raptor constructs
detected via an HA tag at the N-terminus or via an anti-raptor
antibody, which detected both the endogenous raptor polypep-
tide and the overexpressed raptor constructs. The processing of
raptor was sometimes evident already in non-treated cells for the
WT construct, possibly as a consequence of the stress induced by
the transfection, but it was further increased by STS treatment
(Figure 5b). On the other hand, the cleavage of the DDAAA
construct was clearly reduced compared with the WT or the
AVAAKA raptor constructs, in both treated and untreated cells. A
similar decrease in raptor cleavage was observed with the DDAAA
versus the WT raptor constructs after FasL treatment (Figure 5c).
Interestingly, after overexpression of raptor WT or mutated
constructs in Jurkat T cells, an additional cleavage fragment
appeared at approximately 70–80 kDa after cell death induction
(Figures 5b and c). This faster migrating cleaved band could
correspond to a lower efﬁciency caspase-mediated cleavage site.
Taken together, these experiments highlighted the importance
of the DDADD, amino-acid 939–943 residues (located within the
raptor C-term region, between the HEAT repeats and the WD
repeats), in the caspase-mediated processing of raptor.
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Figure 3. In vitro cleavage of raptor by recombinant caspase-1 and -6. (a) Jurkat T-cell lysates were incubated with two units of recombinant
caspase-1 (C1), caspase-2 (C2), caspase-3 (C3), caspase-6 (C6), caspase-7 (C7), caspase-8 (C8) or caspase-9 (C9) and raptor cleavage was
monitored and compared with a STS-treated Jurkat T-cell lysate. (b) Time-dependant in vitro cleavage of raptor by caspase-1, -3 or -6 in Jurkat
T-cell lysates using two units of each recombinant proteins.
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Raptor is cleaved at the N-terminus part after DEADLTD residues
As shown in Figures 5b and c, the HA tag signal disappeared after
STS or FasL treatment, possibly due to activation of caspases that
could cleave inside the HA tag sequence45 and/or because of the
presence of a raptor N-term cleavage site. To determine the
presence of a potential N-term raptor cleavage site, we used a
recombinant glutathione-S-transferase (GST)-raptor protein. This
recombinant protein has a molecular mass of 70 kDa and contains
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Figure 4. Raptor cleavage by caspase-6 and other caspases. (a) Jurkat T-cell lysates were incubated with recombinant caspases-3, -6, -7 for 2 h.
Cleavage of raptor and physiological substrates of caspases (PARP and lamin A/C) were monitored and compared with the positive control
sample (Jurkat T cells treated with STS for 2 h). (b) The effect of z-VAD-fmk on the recombinant caspase-6-mediated cleavage of raptor in
Jurkat T-cell lysate. (c) Cartoon of recombinant mTORC1 (composed of mLST8, mTOR (1362-end) and recombinant raptor). FAT, focal adhesion
targeting; FRB, FKBP12-rapamycin binding; FATC, C-term focal adhesion targeting. (d) Cleavage of the full-length recombinant raptor (inside
recombinant mTORC1) by recombinant caspase-6, -3 and -7 in the presence (or not) of z-VAD-fmk. (e) WT versus caspase-6 K.O. KBM-7 cells
were treated with STS or FasL for 4 h and then cell lysates were analyzed by SDS-PAGE and western blot.
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the N-term sequence of raptor (amino acid 1–379) fused to the
N-terminus with GST (Figure 5a). Incubation of the N-term
recombinant raptor with recombinant caspase-6 generated a
cleavage of raptor from the 70 kDa into a molecular species of
40 kDa, indicating the presence of a caspase-6-mediated cleavage
site at the beginning of the raptor sequence, after the GST tag
(Figure 5d).
Next, two samples were prepared to identify the raptor N-term
cleavage site(s) by mass spectrometry (MS) (Figure 5e). A tryptic
peptide with sequence LTDWNLPLAFMK was clearly detected,
which resulted from cleavage after an aspartate residue in the
sequence DEAD (amino-acid 20) (Supplementary Figure S2). In
addition, another potential caspase-6-speciﬁc cleavage site
(DEADLTD, amino-acid 23) was found next to the DEAD site. This
potential cleavage site seemed less prone to be cleaved by
caspase-6, as it appeared in much lower amounts as judged by
spectral counts (Supplementary Figure S2). Moreover, recombi-
nant caspase-3 or -7 were also able to process the N-term
recombinant raptor into a 41 kDa fragment, similary to recombi-
nant caspase-6 (Supplementary Figure S3).
Taken together, these data indicated that raptor could be
cleaved in vitro by caspase-6 (and by caspase-3 and -7) after two
N-term aspartate residues localized next to each other as present
in the DEADLTD sequence.
Raptor processing correlates with mTORC1 inhibition and cell
death
As raptor has an important role as a scaffold protein within
mTORC1, the processing of raptor could have a negative effect on
mTORC1 structure and activity. To assess whether the processing
of raptor led to the inhibition of mTORC1 signaling, the down-
stream targets of mTORC1 were analyzed for phosphorylation, as
well as the phosphorylation of mTOR at Ser2448 by an upstream
activator, Akt.46,47 Incubation of Jurkat T cells with STS or FasL for
2, 4 and 6 h led to progressive cleavage of raptor, whereas
phosphorylation levels of mTOR, 4E-BP1 and S6K were all
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Figure 5. Cleavage of raptor at the C-term DDADD (amino acids 939–943) residue and at the N-term DEADLTD (amino acids 17–23) residue.
(a) Cartoon of raptor and its putative C-term caspase-mediated cleavage residues (UniProtKB: Q8N122). The recombinant N-term raptor
protein (amino acids 1–379) is represented by the arrow. Different N-term tags (HA or GST) were used according to the raptor constructs. (b)
Jurkat T cells were transfected with GFP, WT, DDAAA or AVAAKA raptor and treated with STS for 2 h. (c) Jurkat T cells were transfected with
GFP, WT or DDAAA raptor and treated with FasL for 2 h. (d) Recombinant N-term raptor was incubated with recombinant caspase-6 for 2 h in
the presence (or in the absence) of z-VAD-fmk. (e) Recombinant raptor was incubated with recombinant caspase-6 and directly inactivated at
95 °C for 10 min or incubated for 3 h at 37 °C. The samples were analyzed by tandem MS.
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decreasing after incubation with STS or FasL (Figure 6a). As STS is a
protein kinase inhibitor, a decrease in multiple phosphorylation
events was expected. However, FasL has no direct effect on
protein kinase activity and nevertheless, the same decrease of
phosphorylation of mTOR substrates was observed, suggesting
that the effect on their phosphorylation was linked to the
processing of raptor. Thus, activation of caspase-3 and -6, as well
as cleavage of their respective substrates (PARP, lamin A/C),
correlated perfectly with cleavage of raptor and with loss of
phosphorylation of 4E-BP1 and S6K.
Although raptor is essential for binding and recruiting mTOR
substrates,15 several studies showed that treatment with curcumin
or with high concentrations of rapamycin induced the weakening
of the raptor–mTOR interaction,34,36 which could affect the
mTORC1 activity. Figure 6b showed by immunoprecipitation (IP)
that mTOR was bound to raptor in the untreated sample, but the
interaction was strongly reduced in the STS-treated sample and no
processed band was observed at 100 kDa after IP, suggesting that
raptor cleavage weakens the mTOR–raptor interaction and that
the cleaved raptor is probably released from the complex.
As the mutation of the C-term raptor cleavage site abolished
raptor processing after apoptosis induction, and the interaction
between raptor and mTOR was altered when raptor was cleaved,
we hypothesized that the absence of raptor processing could lead
to a difference in cellular survival under stress conditions. For this
reason, we investigated the effect of overexpressing a cleavage-
resistant mutant of raptor (DDAAA) versus WT raptor on apoptosis
induction (Figure 6c). Apoptosis induction with STS had a strong
effect on cells transfected with the raptor WT construct (almost
90% of dead cells), whereas cells transfected with cleavage-
resistant raptor (DDAAA) showed a signiﬁcative reduction in STS-
induced cell death (nearly 60%). Thus, raptor cleavage had an
important role in the apoptotic cascade, as the abolition of its
processing induced resistance against cell death.
Taken together, these results suggested that raptor processing
correlated with its dissociation from mTORC1, loss of phosphor-
ylation of mTOR substrates and thus, inactivation of the mTORC1
during apoptosis.
DISCUSSION
In this study, we investigated the molecular mechanisms involved
in the targeting of mTORC1 by anticancer drugs, as this complex is
frequently hyperactivated in human cancers. Treatment of
different lymphoma T- and B-cell lines with anticancer drugs like
cisplatin, etoposide, rapamycin, curcumin and apoptosis inducers
like STS and FasL led to the processing of the 150 kDa raptor
protein into a smaller fragment of 100 kDa. Interestingly,
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Figure 7. Model representing mTORC1 modulation from cell growth to apoptosis.
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rapamycin is known as an allosteric inhibitor of mTORC1, which, at
low concentrations, binds to the intracellular protein FKBP12 to
form a gain-of-function complex, inducing inhibition of mTORC1.
Repression of mTORC1 by low dose of rapamycin will give rise to
induction of autophagy, as mTORC1 normally blocks initiation of
autophagy through Unc-51 like autophagy activating kinase 1
(ULK1) inhibition. Contrariwise, high doses (deﬁned as 20 μM) of
rapamycin were shown to induce apoptosis (cleavage of PARP) as
well as mTOR-raptor dissociation and loss of phosphorylation of
4E-BP1.36,39 The precise mechanism of action of rapamycin (at
high dose) has not been described but our results can explain the
missing gap, as we showed that rapamycin (as well as other drugs)
led to caspase activation (Supplementary Figures S4 and S5),
which cleaved raptor, dislocated and therefore inhibited the
mTORC1. In our hands, both high and low concentrations of
rapamycin gave rise to processing of raptor and activation of
caspases in different cell lines and with varying kinetics (Figure 1d
and Supplementary Figure S5). In addition, drugs triggering either
the intrinsic (cisplatin, etoposide, STS) or the extrinsic (FasL)
apoptosis cascades induced raptor processing, which indicated
that different cell death stimuli converged to raptor cleavage.
Here we identiﬁed caspase-6 as a key protease involved in the
cleavage of raptor at the C-term and at the N-term, but other
caspases could have a redundant role, as some processing of
raptor was still present in caspase-6 KO cells. This is coherent
considering the importance of mTORC1 as a major regulator of
cellular anabolic processes. Therefore, different caspases most
likely act together to process raptor, inhibit the mTORC1 and thus
block cell growth.
The identiﬁcation of caspase-mediated raptor cleavage sites
revealed that the C-term cleavage site was located between the
HEAT repeats and the WD repeats, whereas the N-term cleavage
site was situated at the beginning of raptor N-term conserved
(RNC) domain. The 3-dimensional (3D) structure of the mTORC1
has been resolved using cryo-electron microscopy and revealed
the dimeric aspect of the complex.12,13 In fact, raptor is situated at
the interface between two mTOR molecules and the overall
structure of the complex is forming a circle-like shape. Based on
this 3D structure, the C-terminus of raptor is situated in between
two mTOR proteins, but the N-terminus of raptor is free and
located at the outside of mTORC1, probably to access more easily
mTOR substrates such as 4E-BP1 and S6K. We would expect that
processing after the DDADD C-term cleavage site destabilizes the
complex, as this site is situated at the point of contact with two
mTOR proteins. The N-term DEADLTD raptor cleavage site could
affect the binding of 4E-BP1 and S6K to raptor and thus, reduce
their phosphorylation. Furthermore, a previous study highlighted
that mutagenesis in the RNC or in the WD repeats of raptor gave
rise to a loss of the mTOR–raptor interaction.14 Thus, raptor
cleavage, which removes a part of the RNC domain and the WD
repeats, could abolish this interaction as well. This hypothesis was
clearly supported by our experiments, which showed a correlation
between raptor cleavage, decrease of raptor-mTOR binding and
loss of phosphorylation of mTOR, S6K and 4E-BP1 (Figures 6a
and b). Moreover, cleavage of raptor in its C-term region could
induce a loss of phosphorylation via the release of the cleaved
raptor fragment from mTORC1. In this scenario, the processed
portion of raptor (unbound and outside mTORC1) could compete
with the remaining unprocessed raptor (bound and inside
mTORC1) for mTOR substrates and thus, decrease the amount of
phosphorylated S6K and 4E-BP1.
Interestingly, the cleavage of raptor had a strong effect at the
cellular level, as the transfection of the cleavage-resistant raptor
mutant (DDAAA) conferred resistance to cell death compared with
transfection with WT raptor. This indicated that the processing of
raptor was required during the apoptosis cascade to properly
deactivate the mTORC1 function and stop cell growth. Collectively,
our ﬁndings support a model (Figure 7) in which either intrinsic or
extrinsic apoptosis pathways lead to activation of executioner
caspases (caspase-3, -6 and -7), which cleave raptor at two speciﬁc
cleavage sites (at least). These cleavage events give rise to a
decrease in the raptor–mTOR interaction and the release of the
cleaved raptor from the mTORC1. The mTORC1 is dislocated and
inactivated (loss of mTOR substrates phosphorylation), which is
crucial to execute the cell death cascade.
An important consequence of our ﬁndings is that the
processing of raptor can now be used as a new marker of
apoptosis and as a complementary indicator of mTORC1 inhibi-
tion. As phosphorylations are sometimes difﬁcult to interpret, the
cleavage of raptor is a novel precise indicator of mTORC1
inactivation, caspase activation and efﬁcient triggering of the cell
death cascade. Novel strategies are required to target the
mTORC1, circumvent drug-resistance and stop cancer progression.
Our study may also have direct applications for drug screening, as
the cleavage of raptor can be used as a selecting marker for the
identiﬁcation of mTORC1-targeting drugs.
MATERIALS AND METHODS
Antibodies, reagents and drugs
Anti-raptor (cat. no. 2280), anti-mTOR (cat. no. 2983), anti-phospho-mTOR
Ser2448 (cat. no. 5536), anti-4E-BP1 (cat. no. 9452), anti-phospho-4E-BP1
Thr37/46 (cat. no. 2855), anti-p70 S6K (cat. no. 9202), anti-phospho-S6K
Thr389 (cat. no. 9234), anti-cleaved-caspase-7 (cat. no. 9491), anti-cleaved-
caspase-6 (cat. no. 9761), anti-caspase-6 (cat. no. 9762), anti-caspase-3 (cat.
no. 9662), anti-PARP (cat. no. 9542), anti-lamin A/C (cat. no. 2032) and anti-
IL-1β (cat. no. 12242) antibodies were purchased from Cell Signaling
Technologies (Danvers, MA, USA). Anti-caspase-1 (cat. no. SC514) antibody
was obtained from Santa Cruz Biotechnology (Dallas, TX, USA). Anti-α-
tubulin (cat. no. T6074) and anti-HA Tag (cat. no. H3663) were ordered from
Sigma (St. Louis, MO, USA).
Cisplatin (cat. no. ALX-400-040), etoposide (cat. no. BML-GR307-0100),
rapamycin (cat. no. BML-A275-0005), STS (cat. no. ALX-380-014-M001) and
Dec-RVKR-cmk (cat. no. ALX-260-022) were all ordered from Enzo Life
Sciences (Farmingdale, NY, USA). Curcumin (cat. no. C1386) and E64D (cat.
no. E3132) were purchased from Sigma. The irreversible, cell permeable
broad-spectrum caspase inhibitor (z-VAD-fmk, cat. no. N-1510-0005) was
obtained from Bachem (Bubendorf, Switzerland). Active recombinant
caspases-1, -2, -3, -6, -7, -8, -9 (cat. no. BV-K232-2) were ordered from MBL
(Woburn, MA, USA). Recombinant human mTOR/Raptor/mLST8 (cat. no.
SRP0364) was purchased from Sigma. Recombinant N-terminus Raptor
(cat. no. ab112419) was purchased from Abcam (Cambridge, UK). The
recombinant FasL (Fc:FasL) was kindly provided by Professor Pascal
Schneider.40 The sequencing grade modiﬁed trypsin (cat. no. V5111) was
obtained from Promega (Dübendorf, Switzerland).
Cells and cell culture conditions
KBM-7 WT and caspase-6 deﬁcient cells (cat. no. P01285E07) were
purchased from Horizon-Genomics (Cambridge, UK). T and B lymphoma
cell lines were cultured in RPMI-1640 (Gibco, Carlsbad, CA, USA)
supplemented with 10% FCS, 1% HEPES and 1% penicillin (10 000 IU/ml)
and streptomycin (10 000 μg/ml). KBM-7 cell lines were maintained in
IMDM (Gibco) supplemented with 10% FCS, 1% HEPES and 1% penicillin
(10 000 IU/ml) and streptomycin (10 000 μg/ml). Cells were cultured at
37 °C with 5% CO2 and splited every 2 days.
Drug treatments and western blot
Cells were seeded in 12-well plates at 106 cells/ml in 1 ml in culture
medium and drugs were added for various period of time. Cells were
recovered, spun down for 5 min at 500× g and pellets were resuspended
in 1x RIPA buffer (Bio Basic Inc., Markham, Canada)/cat. no. RB4478)
containing protease/phosphatase inhibitors (Cell Signaling Technologies/
cat. no. 5872S) and kept on ice for lysis for 20 min. Cleared cell lysates were
obtained after 5-min centrifugation at 14 000× g. Cell lysates were dosed
for protein concentration using a BCA protein assay kit (Thermo Scientiﬁc,
Zug, Switzerland)/cat. no. 23225). Thirty microgram of protein was loaded
on 8% or 12% SDS-PAGE. Standard western blot procedure was followed.
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In vitro caspase reaction
Jurkat T cells (5 × 105 cells per condition) were lysed in 10 μl of 1x RIPA
buffer without protease/phosphatase inhibitors. Cell lysate was incubated
in 30 μl of 1x caspase reaction buffer (50 mM HEPES, pH 7.2, 50 mM NaCl,
0.1% CHAPS, 10 mM EDTA, 5% glycerol and 10 mM DTT) with two units of
various recombinant caspases. The reaction was performed at 37 °C for 2
to 4 h. Reactions were stopped by the addition of sample buffer and
boiling of the sample for 5 min at 95 °C. For the in vitro caspase reactions
performed on recombinant mTOR/Raptor/mLST8 or on recombinant
N-terminus Raptor, 1–2 μg of recombinant protein were added directly
into the caspase reaction buffer in the presence of recombinant caspases.
Caspase-1 activation in BMDMø
BMDMø were generated from C57BL/6 mice using standard protocol.41
BMDMø were plated in 48-well plates at 2.5 × 105 cells per well. The
priming step was performed with ultrapure LPS (Labforce, Muttenz,
Switzerland) (100 ng/ml) for 3 h. Following priming, the inﬂammasome
was activated with 5 μM Nigericin (Sigma) or 5 mM ATP for 1 h.
Supernatants were collected and proteins were precipitated using
methanol–chloroform protocol. Cell lysates were collected using 1x RIPA
buffer.
MS analysis
Recombinant N-terminus raptor (500 ng) was incubated with two units (U)
of recombinant caspase-6 and boiled for 10 min at 95 °C or incubated at
37 °C for 3 h. Samples were run on a 10% SDS-PAGE and stained overnight
with colloidal Coomassie blue and then destained. Interesting bands were
cut and partially digested with trypsin (1 h 30-min incubation) into
peptides, which were then analyzed by nano-HPLC and high-resolution
tandem MS (nanoLC-MS/MS). The database searching software MASCOT
(Boston, MA, USA) was used to match the generated spectra to known
protein sequences with a mass tolerance of 10 p.p.m. for the precursor
peptide mass and 0.5 Da for tandem MS fragments. Cleavage speciﬁcity for
peptide matching was semi-tryptic (only one cut C-term to Lys and Arg
was required).
Raptor vectors
HA WT raptor plasmid was a gift from David Sabatini (Addgene plasmid
# 8513, Cambridge, MA, USA).14 Raptor mutants (DDAAA/AVAAKA) were
generated by Genscript (Piscataway, NJ, USA).
Transfections
Jurkat T cells were transfected using Amaxa Cell line Nucleofector Kit V
(Lonza, Visp, Switzerland/cat. no, VCA-1003) following the manufacturer’s
protocol. After overnight incubation at 37 °C with 5% CO2, fresh RPMI was
added on the cells for another 24-h incubation. Fourty-eight hours post
transfections, cell death was induced either with FasL (50 ng/ml) or STS
(2 μM) for 2–4 h.
Immunoprecipitation
Six million Jurkat T cells were treated with 2 μM of STS for 6 h or left
untreated. Cells were washed once in PBS and resuspended in a lysis buffer
containing 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 0.3% CHAPS
and 1/100 protease/phosphatease inhibitor cocktail (Cell Signaling
Technologies, cat. no. 5872S). Cells were left 20 min on ice and centrifuged
at 14 000× g for 5 min to obtain cleared cell lysates. Cell lysates were
incubated with gentle rocking with anti-mTOR antibody (Cell Signaling
Technologies, cat. no. 2983, dilution 1/50) for an overnight incubation at
4 °C. The next day, protein A/G PLUS-agarose beads (Santa Cruz
Biotechnology, cat. no. sc-2003) was added to the cell lysate/antibody
mix for an additional 3-h incubation with gentle rocking at 4 °C. Then
beads were washed with lysis buffer ﬁve times, SDS sample buffer was
added, samples were heated for 5 min at 95 °C and loaded on a 6% SDS-
PAGE for wertern blot analysis.
Cell death sensitivity test
Fourty-eight hours post transfection, cells were treated with STS (2 μM)
for 4 h or left untreated. Then cells were stained using the LIVE/DEAD
ﬁxable far red dead cell stain kit (cat. no. L10120, Invitrogen, Waltham, MA,
USA) following the manufacturer’s protocol. Cell death was quantiﬁed by
ﬂow cytometry (Accuri C6 ﬂow cytometer, Ann Arbor, MI, USA). Statistical
signiﬁcance of differences was calculated using unpaired Student’s t-test
with the Prism software (Irvine, CA, USA).
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